IAMA Therapeutics’ Post

Accelerating  Drug Discovery in CNS Disorders

🌟 Accelerating  Drug Discovery in CNS Disorders 🌟 Billions are invested in drug discovery every year, yet the clinical failure rate remains dauntingly high. We understand the complexities and challenges our sponsors face in developing effective treatments for central nervous system (#CNS) disorders. 🔬 As a forerunner in the field of preclinical EEG, SynapCell benefits from unique expertise and know-how in this domain based on 20 years of experience. We offer a  comprehensive range of assays, from efficacy and derisking assays to model exploration, and ensures that drug candidates are thoroughly evaluated at every stage. Utilizing cutting-edge in vivo compound testing and EEG #biomarkers, we predict the efficacy of drug candidates early in the preclinical phase, significantly increasing the likelihood of clinical success. 🧠 Whether you are working on #epilepsy, #Parkinson’s disease or other movement disorders, #psychiatric and #neurodegenerative disorders, our translational #neuroscience expertise can guide you from discovery to successful clinical outcomes. Discover how SynapCell can revolutionize and accelerate your drug development process. Let's push the boundaries of neuroscience together! 🔗 Learn more about our services : https://synapcell.fr/ #DrugDiscovery #CNSdisorders  #PreclinicalResearch

At Kapoose Creek Bio, we're continuing to share our science at major conferences. Last week, Dr. Timsy Bhando presented a poster at the 7th Annual Neuropsychiatric Drug Development Summit in Boston, highlighting research on our lead molecule KCB-100. KCB-100 shows neurotrophic, neuritogenic, and synaptogenic activities, working through the BDNF (brain-derived neurotrophic factor) signalling pathway. BDNF is critical for neuron survival, growth, and synaptic plasticity, and this molecule’s ability to activate these pathways presents exciting opportunities for treating neurodegenerative diseases and improving brain health. To top it off, KCB-100 also demonstrates blood-brain barrier (BBB) permeability in in-vivo models, bringing us one step closer to delivering effective CNS therapies. Kapoose Creek Bio is thrilled to leverage our AI technology to optimize the KCB-100 compound for human dosing, inching ever closer towards the clinical development of a Drug Candidate in the coming months. Exciting times! #Neuroscience #BDNF #DrugDiscovery #CNSResearch #BloodBrainBarrier #Neurotrophic #Neurodegeneration #PharmaInnovation

Our novel therapeutic approach targets a mechanism of action to promote #neurogenesis and #neuroprotection. Learn more about how dysreglations in this naturally occurring process leads to #neurologicaldisorders. https://lnkd.in/gmaxiKzx

Early identification could allow the treatment of patients even before symptoms occur, which is the endgame for a disease-modifying approach such as our drug candidate GT-02287. #neurodegeneration #parkinsons #als #neurosciences Researchers develop new blood test to identify risk of Parkinson’s disease The findings could help to identify people most likely to benefit from disease-modifying therapies https://lnkd.in/eGkXBijs

Excited to announce that PsychoGenics will be at the Society for Neuroscience (SfN) 2024 Annual Meeting! 🧠🔬 Visit us at booth #325 to learn about our cutting-edge work in Neurodegeneration, Abuse Liability, and Pain research. Don't miss our poster presentations: Utilizing rat kindling models for anti-epileptic drugs screening (B122, Oct 5) Parkinson's Disease: Molecular and Genetic Studies (C93, Oct 5) Comparison of rat models of vascular headache and trigeminal sensitization (C103, Oct 6) In vivo PK, side effect profile, and analgesic efficacy of multiple compounds (C150, Oct 6) Characterization of a SOD1 Rat Model of ALS (B103, Oct 6) Characterization of the Ube3a Mouse Model of Angelman Syndrome (A5, Oct 6) Evaluation of the abuse liability of gabapentin and duloxetine in rats (O12, Oct 8) Locomotor and sensory behavior changes in spinal cord injury model (D35, Oct 8) We're looking forward to sharing our latest findings and connecting with fellow neuroscience enthusiasts. See you there! #SfN2024 #Neuroscience #DrugDiscovery #PreclinicalResearch #PsychoGenics

Excited to announce that PsychoGenics will be at the Society for Neuroscience (SfN) 2024 Annual Meeting! 🧠🔬 Visit us at booth #325 to learn about our cutting-edge work in Neurodegeneration, Abuse Liability, and Pain research. Don't miss our poster presentations: Utilizing rat kindling models for anti-epileptic drugs screening (B122, Oct 5) Parkinson's Disease: Molecular and Genetic Studies (C93, Oct 5) Comparison of rat models of vascular headache and trigeminal sensitization (C103, Oct 6) In vivo PK, side effect profile, and analgesic efficacy of multiple compounds (C150, Oct 6) Characterization of a SOD1 Rat Model of ALS (B103, Oct 6) Characterization of the Ube3a Mouse Model of Angelman Syndrome (A5, Oct 6) Evaluation of the abuse liability of gabapentin and duloxetine in rats (O12, Oct 8) Locomotor and sensory behavior changes in spinal cord injury model (D35, Oct 8) We're looking forward to sharing our latest findings and connecting with fellow neuroscience enthusiasts. See you there! #SfN2024 #Neuroscience #DrugDiscovery #PreclinicalResearch #PsychoGenics

On this #WorldBrainDay let's remember that brain disorders are a major source of suffering globally. With over 3.4 billion people affected by nervous system disorders and 11.1 million deaths annually, advancing research is imperative. This #WBD24, let’s prioritize collaboration and advancement of research. We at Aganitha are humbled to contribute to CNS research. Our recent collaboration with CSIR-CCMB to develop nanobody binders targeting GluD1 receptors is a significant stride for us in neuroscience and pharmacology. These nanobodies might serve as precise molecular tools to modulate GluD1 receptor activity, potentially unlocking novel therapeutic avenues for neurological disorders. Complementing wet lab techniques, in our recent preprint, we analyzed drug selectivity in an approved drug for relapsing forms of Multiple sclerosis. Our work shows that MD powered in silico studies can model and predict selectivity of candidate molecules to GPCRs, the largest family of drugs targeted by approved drugs. #WorldBrainDay 2024 provides an occasion to remind ourselves of the importance of these research activities & collaborations. Research into CNS disorders can alleviate individual suffering & have positive implications for all of humanity.  #WorldBrainDay #Neuroscience #BrainHealth #Aganitha #Biopharma #Innovation #Prevention #Awareness #Collaboration #Education #Advocacy #who #WBD  #CNS #neurological disorders #Alzheimer's #MS #Nanobody #Epilepsy #research

We are thrilled to announce that EnClear Therapies has been awarded a prestigious grant from the National Institutes of Health - National Institute of Neurological Disorders and Stroke (NIH-NINDS)! 🏆 Grant#: 1R44NS135792-01 📚 Title: Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - EnClear Precision CNS Delivery System 👩🔬 Principal Investigator: Marcie A. Glicksman 🏢 Organization: EnClear Therapies, Inc. This grant will propel our groundbreaking work in developing the Enclear Precision System for targeted delivery of therapeutics into the central nervous system, offering hope for innovative treatments in neurological disorders. We are immensely grateful to NIH-NINDS for their support and recognition of our research efforts. Special thanks to our dedicated team of physician and scientist partners, as well as our collaborators and the EnClear team, whose commitment and hard work have made this achievement possible. William Brian Gormley, MD, MPH, MBA, Marcie Glicksman, Rajan Patel, Dan Elbaum, Sandy Hinckley, Gregory Martin, Ph.D., Maria Paikos-Hantzis, Kevin Kalish, Anthony DePasqua Stay tuned for more updates as we continue our mission to advance neurotherapeutics and make a meaningful impact in patients' lives. #NIHGrant #NINDS #Neuroscience #CSFDrugDelivery #EnclearTherapies #ResearchExcellence #precisiondosing

𝗣𝘂𝗿𝗽𝗹𝗲 𝗗𝗮𝘆: 𝗨𝗻𝗶𝘁𝗲𝗱 𝗳𝗼𝗿 𝗘𝗽𝗶𝗹𝗲𝗽𝘀𝘆 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 🧠🎗️🟣 Epilepsy is one of the predominant CNS disorders, characterized by mutations in ion channels such as NaV, CaV, KCNQ, and GABA(A) receptors. These mutations can lead to seizures, prompting researchers to seek both activators and inhibitors of these channels. High throughput patch clamp electrophysiology is key in this quest, allowing for detailed studies and the discovery of new seizure-preventing ligands. At Nanion Technologies, we are dedicated to providing exceptional tools and insights that accelerate scientific progress and therapeutic discovery, to ultimately improve lives. 🟣 𝗪𝗲𝗮𝗿 𝗣𝘂𝗿𝗽𝗹𝗲, 𝗦𝘁𝗮𝗻𝗱 𝗨𝗻𝗶𝘁𝗲𝗱 Today, on purple day we raise awareness about epilepsy and show solidarity to the 65 million individuals courageously living with this condition. Discover the role of ion channels in epilepsy and other neurological diseases: https://ow.ly/9LFM50QZxey #PurpleDay #EpilepsyAwareness #Neuroscience #IonChannels